Cisar, Justin S.; Pietsch, Christine; DeRatt, Lindsey G.; Jacoby, Edgar; Kazmi, Faraz; Keohane, Colleen; Legenski, Katie; Matico, Rosalie; Shaffer, Paul; Simonnet, Yvan; Tanner, Alexandra; Wang, Chao-Yuan; Wang, Weixue; Attar, Ricardo; Edwards, James P.; Kuduk, Scott D. published the artcile< N-Heterocyclic 3-Pyridyl Carboxamide Inhibitors of DHODH for the Treatment of Acute Myelogenous Leukemia>, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is heterocyclic pyridyl carboxamide preparation dihydroorotate dehydrogenase inhibitor docking.
Dihydroorotate dehydrogenase (DHODH) is an enzyme well-known in the pyrimidine biosynthesis pathway; however, small mol. DHODH inhibitors were recently shown to induce differentiation in multiple AML subtypes. Using virtual screening and structure-based drug design approaches, a new series of N-heterocyclic 3-pyridyl carboxamide DHODH inhibitors were discovered. Two lead compounds, had potent biochem. and cellular DHODH activity, favorable physicochem. properties, and efficacy in a preclin. model of AML.
Journal of Medicinal Chemistry published new progress about Dihydroorotate dehydrogenase inhibitors. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Safety of (9Z,12Z)-Methyl octadeca-9,12-dienoate.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics